SALANI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 701
EU - Europa 489
AS - Asia 243
AF - Africa 83
Totale 1.516
Nazione #
US - Stati Uniti d'America 698
IT - Italia 213
SG - Singapore 139
SE - Svezia 135
CN - Cina 61
CI - Costa d'Avorio 54
BG - Bulgaria 37
GB - Regno Unito 29
AT - Austria 27
NG - Nigeria 19
IN - India 14
DE - Germania 13
SN - Senegal 10
PL - Polonia 9
TR - Turchia 9
HK - Hong Kong 7
VN - Vietnam 7
FI - Finlandia 5
RO - Romania 4
CA - Canada 3
CH - Svizzera 3
FR - Francia 3
IR - Iran 3
BE - Belgio 2
ES - Italia 2
AL - Albania 1
CZ - Repubblica Ceca 1
EE - Estonia 1
IE - Irlanda 1
JP - Giappone 1
LK - Sri Lanka 1
MY - Malesia 1
NL - Olanda 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 1.516
Città #
Chandler 90
Singapore 75
Santa Clara 56
Fairfield 55
Abidjan 54
Boardman 51
New York 45
Milan 43
Sofia 37
Ashburn 36
Seattle 30
Florence 29
Vienna 27
Pisa 21
Woodbridge 20
Lagos 19
London 19
Lawrence 18
Princeton 18
Cambridge 17
Wilmington 16
Kent 13
Ogden 12
Shanghai 12
Houston 11
Hyderabad 11
Medford 11
Dakar 10
Quanzhou 10
Beijing 9
Istanbul 9
Council Bluffs 8
Warsaw 8
Ann Arbor 7
Hong Kong 7
Los Angeles 7
San Diego 7
Fuzhou 6
Frankfurt am Main 5
Lappeenranta 5
Norwalk 5
Rome 5
Vicopisano 5
Castiglione Chiavarese 4
Piombino 4
Bremen 3
Cascina 3
Center 3
Fort Worth 3
Hangzhou 3
Livorno 3
Massa 3
Santa Croce sull'Arno 3
Toronto 3
Turin 3
Bologna 2
Brussels 2
Eagleville 2
Ebikon 2
Farra di Soligo 2
Forlì 2
Lucca 2
Messina 2
Modugno 2
Munich 2
Padova 2
Philadelphia 2
Romainville 2
Serra 2
Sesto San Giovanni 2
Venice 2
Barletta 1
Bern 1
Bucharest 1
Carugate 1
Casaleone 1
Changsha 1
Ciampino 1
Dong Ket 1
Dublin 1
Formigine 1
Fulham 1
Garbagnate Milanese 1
Guangzhou 1
Islington 1
Kashan 1
Minerbio 1
Minneapolis 1
New Delhi 1
North Charleston 1
Olomouc 1
Paris 1
Pietrasanta 1
Prineville 1
Redmond 1
Redwood City 1
Rosignano Marittimo 1
Shenzhen 1
Southwark 1
Springfield 1
Totale 1.058
Nome #
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 116
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 95
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 84
Invasive Meningococcal Disease due to group C N. meningitidis ST11 (cc11): The Tuscany cluster 2015–2016 79
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 76
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 75
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 65
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 64
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 55
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 50
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 50
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 47
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 45
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 44
In Reply 43
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 42
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients 42
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 34
Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 33
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 32
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice 32
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 30
Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 28
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 27
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 26
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 24
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 23
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 19
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 18
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 17
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 16
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 15
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer 15
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 14
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 11
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 11
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 11
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 11
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 10
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 10
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 9
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 9
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 9
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 9
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 8
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 7
Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Carcinomatosis: The Need for Clear Answers Through Proper Questions 6
Comprehensive analysis of differentially expressed miRNAs in hepatocellular carcinoma: Prognostic, predictive significance and pathway insights 6
Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution 5
Totale 1.607
Categoria #
all - tutte 8.260
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.260


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202060 0 0 0 0 4 5 9 9 8 5 17 3
2020/202196 6 2 4 5 6 20 3 5 11 11 10 13
2021/2022204 0 1 3 6 42 41 6 2 19 14 22 48
2022/2023465 50 70 34 15 51 59 6 36 94 2 39 9
2023/2024424 21 41 42 26 58 40 65 16 5 17 41 52
2024/2025342 14 102 48 85 93 0 0 0 0 0 0 0
Totale 1.607